- Precigen Reports Full Year 2023 Financial Results and Business Updates
- Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
- Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
- Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
More ▼
Key statistics
On Wednesday, Precigen Inc (PGEN:NSQ) closed at 1.45, -22.87% below its 52-week high of 1.88, set on Aug 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.41 |
---|---|
High | 1.45 |
Low | 1.39 |
Bid | 1.43 |
Offer | 1.44 |
Previous close | 1.45 |
Average volume | 1.17m |
---|---|
Shares outstanding | 248.92m |
Free float | 220.75m |
P/E (TTM) | -- |
Market cap | 360.93m USD |
EPS (TTM) | -0.3933 USD |
Data delayed at least 15 minutes, as of Mar 27 2024 20:00 BST.
More ▼